Javascript must be enabled to continue!
Development and Validation of Comorbidity Index to Predict In-hospital Mortality Risk for Patients with Steven-Johnson Syndrome
View through CrossRef
Abstract
Background
Stevens-Johnson Syndrome (SJS)/toxic epidermal necrolysis (TEN) is a spectrum of severe drug reactions that has a high in-hospital mortality from 5% to 20%. Early risk prediction for in-hospital mortality in SJS/TEN can be informative for clinical management. This study aimed to develop an in-hospital mortality risk calculator for SJS based on patient comorbidities.
Methods
Patients who were diagnosed with SJS/TEN were identified in the National Inpatient Sample database between Q4 2015-2020. SJS patients were randomly sampled into two equal experimental and validation groups. The weight for each comorbidity was determined from a multivariable logistic regression to develop into a single SJS Index.
Results
There were 4519 SJS (mortality rate 5.05%), 873 SJS-TEN (mortality rate 13.06%), and 759 TEN (mortality rate 17.00%) patients identified. The SJS Index had good discrimination power (
c
-statistic=0.704, 95% CI=0.656-0.753) and was well-calibrated (Brier score=0.049). SJS Index had similar performance in multivariable regression model with all comorbidities (DeLong p-value=0.621) and validation group (DeLong p-value=0.634). The index had significantly better discriminative power than Elixhauser Comorbidity Index (ECI) (DeLong p-value=0.001). Applying the SJS Index to SJS-TEN patients showed comparable discriminative powers (DeLong test p-value=0.284). In TEN patients, SJS Index remained good calibration (Brier score=0.062) but discriminative power decreased (DeLong p-value=0.005). After adjusting for age, race, and ethnicity, SJS Index had improved performance in all groups.
Conclusions
The SJS Index can effectively discriminate and predict in-hospital mortality in SJS and was externally validated in NIS. SJS/TEN often has emergent presentation and immediate intervention is required, this risk score can give an initial assessment of the mortality based on medical records alone and thus offer a quick insight for clinicians for management. In addition, this study demonstrated the possibility of the SJS Index being used as one composite metric to develop a more comprehensive risk-calculator score.
Title: Development and Validation of Comorbidity Index to Predict In-hospital Mortality Risk for Patients with Steven-Johnson Syndrome
Description:
Abstract
Background
Stevens-Johnson Syndrome (SJS)/toxic epidermal necrolysis (TEN) is a spectrum of severe drug reactions that has a high in-hospital mortality from 5% to 20%.
Early risk prediction for in-hospital mortality in SJS/TEN can be informative for clinical management.
This study aimed to develop an in-hospital mortality risk calculator for SJS based on patient comorbidities.
Methods
Patients who were diagnosed with SJS/TEN were identified in the National Inpatient Sample database between Q4 2015-2020.
SJS patients were randomly sampled into two equal experimental and validation groups.
The weight for each comorbidity was determined from a multivariable logistic regression to develop into a single SJS Index.
Results
There were 4519 SJS (mortality rate 5.
05%), 873 SJS-TEN (mortality rate 13.
06%), and 759 TEN (mortality rate 17.
00%) patients identified.
The SJS Index had good discrimination power (
c
-statistic=0.
704, 95% CI=0.
656-0.
753) and was well-calibrated (Brier score=0.
049).
SJS Index had similar performance in multivariable regression model with all comorbidities (DeLong p-value=0.
621) and validation group (DeLong p-value=0.
634).
The index had significantly better discriminative power than Elixhauser Comorbidity Index (ECI) (DeLong p-value=0.
001).
Applying the SJS Index to SJS-TEN patients showed comparable discriminative powers (DeLong test p-value=0.
284).
In TEN patients, SJS Index remained good calibration (Brier score=0.
062) but discriminative power decreased (DeLong p-value=0.
005).
After adjusting for age, race, and ethnicity, SJS Index had improved performance in all groups.
Conclusions
The SJS Index can effectively discriminate and predict in-hospital mortality in SJS and was externally validated in NIS.
SJS/TEN often has emergent presentation and immediate intervention is required, this risk score can give an initial assessment of the mortality based on medical records alone and thus offer a quick insight for clinicians for management.
In addition, this study demonstrated the possibility of the SJS Index being used as one composite metric to develop a more comprehensive risk-calculator score.
Related Results
If I Had Possession over Judgment Day: Augmenting Robert Johnson
If I Had Possession over Judgment Day: Augmenting Robert Johnson
augmentvb [ɔːgˈmɛnt]1. to make or become greater in number, amount, strength, etc.; increase2. Music: to increase (a major or perfect interval) by a semitone (Collins English Dicti...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
Platform Session B: Clinical Neurophysiology/Clinical Epilepsy
3:00 p.m.–6:00 p.m.
Platform Session B: Clinical Neurophysiology/Clinical Epilepsy
3:00 p.m.–6:00 p.m.
1
Jose F.
Tellez‐Zenteno,
1
Scott B.
Patten, and
1
Samuel
Wiebe
...
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Abstract
Thoracic outlet syndrome (TOS) is a complex and often overlooked condition caused by the compression of neurovascular structures as they pass through the thoracic outlet. ...
The Ability of Comorbidity Indices to Predict Mortality After Heart Transplantation: A Validation of the Danish Comorbidity Index for Acute Myocardial Infarction, Charlson Comorbidity Index, and Elixhauser Comorbidity Index
The Ability of Comorbidity Indices to Predict Mortality After Heart Transplantation: A Validation of the Danish Comorbidity Index for Acute Myocardial Infarction, Charlson Comorbidity Index, and Elixhauser Comorbidity Index
Background
Advanced heart failure patients often have comorbidities of prognostic importance. However, whether total pretransplantation comorbidity burden predicts mort...
External validation of the Global Registry of Acute Coronary Events (GRACE) risk score: insights from the FORCE-ACS registry
External validation of the Global Registry of Acute Coronary Events (GRACE) risk score: insights from the FORCE-ACS registry
Abstract
Background
Acute coronary syndrome (ACS) patients are a heterogeneous group with a varying risk of in-hospital and long...
Siltuximab Treatment Increases Hemoglobin (Hb) Levels: Preliminary Results From a Prospective Phase 1 Study In Refractory Solid Tumors
Siltuximab Treatment Increases Hemoglobin (Hb) Levels: Preliminary Results From a Prospective Phase 1 Study In Refractory Solid Tumors
Abstract
Abstract 5150
Introduction:
Siltuximab is a chimeric monoclonal antibody with high affinity for the infl...
Validation in Doctoral Education: Exploring PhD Students’ Perceptions of Belonging to Scaffold Doctoral Identity Work
Validation in Doctoral Education: Exploring PhD Students’ Perceptions of Belonging to Scaffold Doctoral Identity Work
Aim/Purpose: The aim of this article is to make a case of the role of validation in doctoral education. The purpose is to detail findings from three studies which explore PhD stude...

